CTLA4 and cancer: Additionally, therapeutic antibodies targeting immune checkpoint molecules, such as PD-1, PD-L1, and CTLA-4, have gained considerable prominence in cancer treatment due to their ability to activate immune responses against cancer cells while reducing the side effects associated with conventional chemotherapeutic agents like cisplatin and methotrexate (4, 5).